ThursdayJan 06, 2022 12:00 pm

Clinical Psychologists Cautiously Evaluating Psychedelic-Backed Mental Health Treatment

A new survey has found that mental health professionals believe that psychedelic substances possess psychological benefits. This was despite concerns about the potential neurocognitive and psychiatric risks linked to using psychedelic treatment. Gabrielle Agin-Liebes, the author of the study, stated that while there was a lot of interest in the potential use of psychedelics in clinical care, there also existed a lot of negative attitudes toward psychedelic therapy. She explained that understanding the extent to which psychedelic treatments would be accepted in the healthcare system would help advance the clinical use of these drugs once they received approval for medical…

Continue Reading

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

Continue Reading

WednesdayJan 05, 2022 1:45 pm

Study Finds Psilocybin-Assisted Psychotherapy Effective in Treating Suicidal Ideation in Cancer Patients

Patients with cancer have a high risk of suicidal ideation and suicide, in particular patients in the advanced stages. These individuals often experience a loss of meaning in life and existential distress, which isn’t easily remedied through the use of pharmacological treatments. However, a new study has found that psilocybin when used together with psychotherapy may alleviate suicidal ideation in patients with life-threatening cancers. The improvements observed in patient mental health were maintained months and even years after treatment had been administered. The study’s findings were reported in the “ACS Pharmacology & Translational Science” journal. The researchers, led by Stephen…

Continue Reading

WednesdayJan 05, 2022 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”) Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six…

Continue Reading

TuesdayJan 04, 2022 2:48 pm

Study Finds That Psilocybin’s Therapeutic Effect Isn’t Altered by SSRI Medication

Compass Pathways recently released data that shows that selective serotonin reuptake inhibitor (“SSRI”) drugs can be used together with psilocybin. SSRI drugs are commonly used to treat mental health conditions including anxiety and depression. Estimates show that more than 300 million individuals globally suffer from major depressive disorder, with about one-third of that population not getting finding any help or relief from current therapies. Compass is carrying out a trial for its COMP360 psilocybin formulation, which involves patients on SSRI therapy being administered with one 25 mg dose of its therapeutic formulation. The study found that the treatment outcomes in…

Continue Reading

TuesdayJan 04, 2022 10:39 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Milestone Notice of Allowance for Revolutionary Treatment of Anxiety Disorders

USPTO notice marks important milestone in the expansion of CYBN’s intellectual property portfolio Once issued, patent may have opportunity to cover a broad range of claims Anxiety disorders are one of the most common mental illnesses in the United States Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its commitment to progressing Psychedelics to Therapeutics(TM). The biopharmaceutical company has received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”) in regard to its patent application connected to its investigational deuterated psychedelic tryptamine compound for the potential treatment of anxiety disorders (https://ibn.fm/fpjXm). “The receipt of…

Continue Reading

MondayJan 03, 2022 1:20 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Joins Gamechangers LIVE Podcast; Shares Views on the Evolution of the Psychedelics Industry

Delic Corp is a leading psychedelic wellness platform with a business network which includes psychedelic wellness clinics, psilocybin research facilities, a famed psychedelic wellness event, and dedicated media and e-commerce platforms Delic’s CEO, Matt Stang recently joined the Gamechangers LIVE podcast to share his perspective on the development of the psychedelic industry along with Delic’s commercial evolution Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leading psychedelic wellness platform committed to bringing science-backed benefits to its many stakeholders, has long been known for its role as a trailblazer of new medicines and treatments in the current environment. Its goal is to…

Continue Reading

ThursdayDec 30, 2021 3:45 pm

Washington City Approves Measure to Decriminalize Psychedelic Substances

Last week, the city of Port Townsend became the latest city to decriminalize entheogenic fungi and plants through a measure that was unanimously adopted by the city council of Port Townsend. This Washington State city is the latest city to relax its policy on psychedelic substances. Under the approved measure, laws against natural psychedelic plants including ayahuasca, peyote and magic mushrooms, will be the lowest priority for law enforcement in the city. Natural psychedelic substances are sometimes referred to as entheogenic fungi and plants. The initiative also conveys support for the decriminalization of psychedelic drugs at the federal level. In…

Continue Reading

ThursdayDec 30, 2021 1:19 pm

Psychedelics May Be Key to Effective Dementia Treatment

Dementia is known to affect an individual’s mental processes, leading to loss of cognitive functioning. It is typically caused by brain injury or disease and is marked by impaired reasoning, changes in personality and memory disorders. In its later stages, the disease kills off the brain cells linked to muscle control, gradually limiting the person’s ability to stand, walk and even swallow food. Estimates from the CDC show that more than 5.7 million individuals suffer from dementia and Alzheimer’s disease, a progressive disorder that destroys memory. Projections show that this number could reach roughly 14 million in the next four…

Continue Reading

WednesdayDec 29, 2021 12:33 pm

Congressman Calls on Colleagues to Urge DEA to Permit Psilocybin Access

Rep. Earl Blumenauer is asking fellow legislators to join him in urging the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted. In a letter circulated by Blumenauer, he notes that there are federal as well as state right-to-try legislations that should allow particular patients to access the psychedelic as an investigational treatment. Blumenauer states in the letter that there existed a growing body of evidence pointing to the effectiveness and safety of psilocybin-assisted therapy as a possible way to provide care to people with anxiety and/or…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000